A foray into the Southern Hemisphere with the great Lockie Macdowell who talks us through #qol#PROs
amongst some really important trials - a great listen @kahutcheson@HNSurgeon@VinPaleri@DavidSherMD
https://t.co/GlzphN4mrO
Happy Monday! What a better way to spend a Monday morning commute than listening to the amazing Mererid Evans taking us through TNM9 and what it means for your practice. Please share!
https://t.co/bkn1qltb7S
@BAHNOOfficial@will_oncology@nearlobey@DavidSherMD@drdavidpalma
The identification of the tubarial gland is a really cool story, though I am doubtful that TG-sparing radiotherapy will make a meaningful difference to patient-reported xerostomia.
Sparing the contralateral TG should already effectively be part of standard practice for ipsilateral-only nodal disease, and the ipsilateral TG will receive dose from elective treatment of the RP nodes.
We recently looked at patient-reported outcomes as a function of tubarial gland dose and could not find a significant relationship (and this included patients treated without ENI, so there was a truly variable dose to the TG):
https://t.co/Y579bM8J7A
Pleased as punch to be invited onto the Deep Margin podcast, now a fixture in HN calendar.
Privilege to follow @DavidSherMD@DrUppaluri
Great fun chatting salvage surgery with @nearlobey@will_oncology Serious topic, yet an easy listen. Do tune in https://t.co/iztg4KsqUz
I don't think I've ever had this much fun talking about radiotherapy.
We discussed ENI, immunotherapy (and radiotherapy) in metastatic and non-metastatic HNSCC, oligometastatic disease, to name a few.
#ESMOAsia25
🚨JUPITER-02 Final 6-year OS analysis presented!
1L toripalimab + gem/cis in pts with RM-Nasopharyngeal Ca
Median OS 64.8 vs 33.7 mo
(HR 0.62; p<0.01)
Adjusted post-prog IO: 61.0 vs 25.1 mo (HR O.52)
Confirms long-term toriGP combo efficacy
👇Updated situation of 1L NPC
@OncoAlert@brunolarvol #oncoalertAF
#NPC #Immunotherapy